1. Home
  2. BILL vs RARE Comparison

BILL vs RARE Comparison

Compare BILL & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BILL Holdings Inc.

BILL

BILL Holdings Inc.

HOLD

Current Price

$43.61

Market Cap

3.2B

Sector

Technology

ML Signal

HOLD

RARE

Ultragenyx Pharmaceutical Inc.

HOLD

Current Price

$26.80

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BILL
RARE
Founded
2006
2010
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.7B
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
BILL
RARE
Price
$43.61
$26.80
Analyst Decision
Buy
Strong Buy
Analyst Count
21
20
Target Price
$57.90
$59.10
AVG Volume (30 Days)
2.4M
2.7M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
74.07
7.31
EPS
0.07
N/A
Revenue
$1,462,570,000.00
$673,000,000.00
Revenue This Year
$14.18
$13.12
Revenue Next Year
$13.83
$37.80
P/E Ratio
$589.43
N/A
Revenue Growth
13.36
20.13
52 Week Low
$31.41
$18.29
52 Week High
$57.21
$39.89

Technical Indicators

Market Signals
Indicator
BILL
RARE
Relative Strength Index (RSI) 60.90 36.47
Support Level $42.06 $21.54
Resistance Level $46.70 $27.42
Average True Range (ATR) 1.86 1.54
MACD -0.01 -1.00
Stochastic Oscillator 67.97 0.74

Price Performance

Historical Comparison
BILL
RARE

About BILL BILL Holdings Inc.

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Share on Social Networks: